This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI^®(risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.

SKYRIZI DOSING GUIDE

SKYRIZI PRESCRIBING INFORMATION

ADALIMUMAB PRESCRIBING INFORMATION

skyrizi desktop banner 7.0

skyrizi mobile banner 2

UK-RISN-230338. Date of preparation May 2024.

Find out more about the efficacy of SKYRIZI

Explore the durability of response with SKYRIZI through clinical trials and long-term data in psoriasis and psoriatic arthritis. Start by selecting a study from the menu below.

LONG-TERM DATA

SKYRIZI (LIMMitless)

NMA data

HEAD-TO-HEAD TRIALS

SKYRIZI vs Secukinumab (IMMerge)

SKYRIZI vs Ustekinumab (UltIMMa-1 + UltIMMa-2)

SKYRIZI vs Adalimumab (IMMvent)

SKYRIZI IN PsA

KEEPsAKE1 + KEEPsAKE2

SKYRIZI LONG-TERM DATA: NMA data

Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis⁵

Results are not from a head-to-head study.

Limitations of NMAs

Network meta-analyses simultaneously analyse all direct and indirect evidence for comparisons of treatments across the network. The main consideration for limitations in a network meta-analysis are to ensure that the relative contributions of different sources of direct evidence, which may have different study limitations, are accounted for appropriately. Judgments should be made across comparisons, considering potential differences between the populations, treatments, and outcomes by the network meta-analysis.

Limitations of this study

The current analysis is limited to outcomes at 48-56 weeks. This analysis is based on data obtained from 215 RCTs from 689 publications. The results need to be validated using real-world data that reflect actual utilisation and outcomes patterns in the psoriasis population to evaluate its generalisability.

Patients achieving PASI 90 (weeks 48-56)

Adapted from Armstrong AW, et al. 2022.

PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks.

Patients achieving PASI 100 (weeks 48-56)

Adapted from Armstrong AW, et al. 2022.

PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks.

Posterior median for Rate of Any Adverse Events (weeks 48-56)

Adapted from Armstrong AW, et al. 2022.

Posterior median for the Rate of Any Serious Adverse Events (weeks 48-56)

Adapted from Armstrong AW, et al. 2022.

Posterior median for the Rate of Adverse Events leading to Treatment Discontinuation

Adapted from Armstrong AW, et al. 2022.

Objectives

Bayesian network meta-analyses (NMs) were conducted to compare the efficacy (at least a 75/90/100% reduction in PASI score from baseline) and safety outcomes (any adverse event (AE), any serious AE (SAE), and AEs loading to treatment discontinuation) of each treatment evaluated between Weeks 48 and 56 after baseline.

This systematic literature review was originally conducted on December 4,2017, and updated on September 17, 2018, February 19, 2021, and May 2, 2021. The 2021 update incorporates recently licensed biologics in Europe and the US, covering all doses published in randomised controlled trials (RCTs).

Study selection

215 RCTs from 689 publications through May 2, 2021. A total of 14 studies were included in the MAs of long-term efficacy and safety outcomes, while 201 were excluded. The searched databases include Embase, MEDLINE, and the Cochrane library. Additional searches were conducted for the reference lists of included studies, conference proceedings, previous health technology assessment submissions, and clinical trial registries.

Data analysis

Rankings were quantified by the surface under the cumulative ranking curve (SUCRA). The benefit-risk profiles of treatments were assessed by bidimensional plots of the NMA-estimated efficacy and safety outcomes.

Study funding

AbbVie Inc funded the study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the publication. No honoraria or payments were made for authorship.

Select definitions

SUCRA: The surface under the cumulative ranking curve, a simple transformation of the mean rank, is used to provide a hierarchy of the treatments and accounts both for the location and the variance of all relative treatment effects. The larger the SUCRA value, the better the rank of the treatment.

Clear/nearly clear: At least a 75/90/100% reduction in PSI score from baseline improvement in PASI.

Tolerability: Withdrawal due to any adverse event.

Featured content

Biologics in the Real-World Setting (BADBIR)

Discover Dr Kave Shams’ insights on the performance of SKYRIZI in the real-world setting, based on data from the UK BADBIR registry, and how specific attributes of biologic therapies can allow for treatment tailoring to meet the individual needs of patients in your clinical practice.

The Psoriasis Patient with Co-morbidities

A 53 year old male with comorbidities affected by chronic plaque psoriasis since 1981, achieves skin clearance with SKYRIZI and participates in activities such as photography, socialising, and walking.

More expert perspectives

View expert perspectives on SKYRIZI’s efficacy
data, dosing regimen and safety profile.

View now

More expert perspectives

View expert perspectives on SKYRIZI’s efficacy data, dosing regimen and safety profile.

View now

UK-RISN-240177. Date of preparation May 2024.

References

Reich K, et al. Lancet 2019; 394: 576-586.
Gordon KB, et al. Lancet 2018; 392: 650-661.
Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
SKYRIZI: Summary of Product Characteristics.
Armstrong AW, et al. Dermatol Ther 2022; 12:167-184.

UK-RISN-240141. Date of preparation: May 2024.

SKYRIZI PRESCRIBING INFORMATION
ADALIMUMAB PRESCRIBING INFORMATION

Important safety information for SKYRIZI^®(risankizumab) in Psoriasis and Psoriatic Arthritis¹
SKYRIZI should be initiated and supervised by healthcare professionals experienced in the diagnosis and treatment of Psoriasis and Psoriatic arthritis.

Some patients may not be suitable for SKYRIZI (risankizumab). You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC) from the links below.

SKYRIZI 150 mg solution for injection in pre-filled pen CLICK HERE.
SKYRIZI 150 mg solution for injection in pre-filled syringe CLICK HERE.

SKYRIZI PRESCRIBING INFORMATION CLICK HERE.

SKYRIZI is contraindicated in patients;

with hypersensitivity to the active substance or to any of the excipients,
with clinically important active infections (e.g. active tuberculosis).

Cautions (See Prescribing Information and SmPC for full details including screening and monitoring requirements):
It is preferable to avoid the use of SKYRIZI during pregnancy. Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment. It is unknown whether risankizumab is excreted in human milk. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.

Dosing in Psoriasis and Psoriatic Arthritis
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.

Adverse reactions
For adverse reactions, please refer to the prescribing information and the SKYRIZI summary of product characteristics available online in the Electronic Medicines Compendium via the links above.

Important safety information for HUMIRA^® (adalimumab) in Psoriasis and Psoriatic Arthritis²
HUMIRA is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which HUMIRA is indicated.

Psoriatic arthritis: HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. HUMIRA has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.
Psoriasis: HUMIRA is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who are candidates for systematic therapy

Paediatric plaque psoriasis: HUMIRA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

Some patients may not be suitable for HUMIRA. You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC).

HUMIRA 40 mg solution for injection in pre-filled pen CLICK HERE.

ADALIMUMAB PRESCRIBING INFORMATION CLICK HERE.

References
1. SKYRIZI Summary of Product Characteristics
2. HUMIRA Summary of Product Characteristics